Teva Pharmaceutical Industries Limited
NYSE:TEVADrug Manufacturers - Specialty & Generic
-$1.09 today
- Market cap
- $49.28B
- Beta
- 0.85
- P/E (TTM)
- 23.1
- EPS (TTM)
- $1.36
Volume 8.86M
Average 6.22M
TEVA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Teva Pharmaceutical Industries LimitedNYSE: TEVA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA turns negative
Q2 FY2026 EBITDA was -$19M, compared with $657M a year earlier. Trailing-twelve-month EBITDA was $2.59B.
Context
- EBITDA amounted to 18.2% of revenue in FY2025, down 8.6 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 9 analysts of $4.68B (+49.0%) for the fiscal year ending Dec 2026, a step up from the -29.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$19M-102.2% QoQ
- Last fiscal yearDec 2025
- $3.14B-29.1% YoY
- LTMJun 2026
- $2.59B-12.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -102.9% | +12.0% | +114.8 pp |
| 1 year | -29.1% | +49.0% | +78.1 pp |
| 3-year CAGR | — | +28.7% | — |
| 5-year CAGR | +18.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 3.14B USD
- Year-over-year change
- -29.1%
- 4-year CAGR
- -8.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.14B | -29.1% |
| FY2024 | 2024-12-31 | 4.43B | +184.4% |
| FY2023 | 2023-12-31 | 1.56B | +268.4% |
| FY2022 | 2022-12-31 | (925M) | -121.0% |
| FY2021 | 2021-12-31 | 4.41B | — |
EBITDA vs competitors
How TEVA compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -12.9% is the 3rd highest of 5, against a peer median of -16.8%.
- EBITDA amounts to 15.0% of revenue for TEVA, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | ₹53.96B INR | -45.2% | +3.8% | 16.3% | |
| LTM Jun 2026 | $2.72B USD | +650.7% | — | 18.4% | |
| LTM Jun 2026 | $2.59B USD | -12.9% | — | 15.0% | |
| LTM Jun 2026 | $652.2M USD | +11.7% | +11.1% | 20.9% | |
| LTM Mar 2026 | $51.83M USD | -62.7% | — | 9.3% | |
| Peer median (excluding TEVA) | — | -16.8% | +7.5% | 17.4% | |
Competitors are the stored peer set for TEVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 15.88B | 14.93B | 15.85B | 16.54B | 17.26B |
| Cost of Revenue | 8.28B | 7.95B | 8.2B | 8.48B | 8.32B |
| Gross Profit | 7.59B | 6.97B | 7.65B | 8.06B | 8.94B |
| Gross Margin | 47.8% | 46.7% | 48.2% | 48.7% | 51.8% |
| Research & Development | 1.09B | 838M | 953M | 1.06B | 1.01B |
| Selling, General & Admin | 3.53B | 3.45B | 3.5B | 3.7B | 3.97B |
| Operating Expenses | 5.88B | 9.17B | 7.21B | 8.37B | 6.78B |
| Depreciation & Amortization | 1.33B | 1.31B | 1.15B | 1.06B | 1B |
| EBITDA | 4.41B | (925M) | 1.56B | 4.43B | 3.14B |
| EBITDA Margin | 27.8% | -6.2% | 9.8% | 26.8% | 18.2% |
| Operating Income | 1.72B | (2.2B) | 433M | (303M) | 2.16B |
| Operating Margin | 10.8% | -14.7% | 2.7% | -1.8% | 12.5% |
| Interest Income | 0 | 0 | 68M | 0 | 0 |
| Interest Expense | 891M | 930M | 1.03B | 941M | 916M |
| Other Income / Expenses | (1.05B) | (945M) | (1.06B) | (980M) | (919M) |
| Income Before Tax | 667M | (3.14B) | (622M) | (1.28B) | 1.24B |
| Pre-Tax Margin | 4.2% | -21.1% | -3.9% | -7.8% | 7.2% |
| Income Tax Expense | 211M | (643M) | (7M) | 676M | (180M) |
| Net Income | 417M | (2.45B) | (559M) | (1.64B) | 1.41B |
| Net Margin | 2.6% | -16.4% | -3.5% | -9.9% | 8.2% |
| EPS (Basic) | 0.38 | (2.20) | (0.50) | (1.45) | 1.23 |
| EPS (Diluted) | 0.38 | (2.20) | (0.50) | (1.45) | 1.20 |
| Weighted Avg Shares | 1.1B | 1.11B | 1.12B | 1.13B | 1.15B |
| Weighted Avg Shares (Diluted) | 1.11B | 1.11B | 1.12B | 1.13B | 1.17B |
Teva Pharmaceutical Industries Limited
NYSE:TEVA
Intrinsic Alpha fair value
Locked
Current Price
$42.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.